৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Products
Payment
Delivery
Indications
Used for treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Not recommended in combination with other potent immunosuppressants.
Pharmacology
Deucravacitinib is a selective TYK2 inhibitor.
It binds to the regulatory domain of TYK2, causing allosteric inhibition of receptor-mediated activation in the JAK-STAT pathway.
This reduces cytokine signaling involved in psoriasis inflammation.
Dosage & Administration
Recommended dose: once daily orally, with or without food.
Do not crush, cut, or chew tablets.
Pediatric use: not established.
Geriatric use: no significant difference observed.
Hepatic impairment: contraindicated in severe cases (Child-Pugh C). No adjustment needed for mild to moderate impairment.
Renal impairment: no dose adjustment required, including ESRD patients on dialysis.
Drug Interactions
No significant pharmacokinetic changes with cyclosporine, fluvoxamine, ritonavir, diflunisal, pyrimethamine, famotidine, rabeprazole.
No significant changes with rosuvastatin, methotrexate, MMF, or oral contraceptives.
Contraindications
Contraindicated in patients with hypersensitivity to Deucravacitinib or its excipients.
Side Effects
Common cold, sore throat, sinus infection.
Cold sores (herpes simplex), canker sores.
Folliculitis, acne.
Serious allergic reactions: facial swelling, breathing difficulty, rash.
Pregnancy & Lactation
Insufficient data in pregnancy.
Unknown if present in human milk.
Risk-benefit assessment required for breastfeeding mothers.
Precautions & Warnings
Hypersensitivity reactions (angioedema) reported.
Increased risk of infections; avoid in active infections.
Evaluate for tuberculosis before initiation.
Malignancies (including lymphoma) observed.
Monitor triglycerides and liver enzymes.
Avoid live vaccines.
Potential risks similar to JAK inhibitors: cardiovascular events, thrombosis, malignancies.
Therapeutic Class
Tyrosine kinase inhibitor.
Storage
Store below 30°C, away from light and moisture.
Keep out of reach of children.






